AI Insight: Johnson & Johnson’s current price is approximately 19% below the PERT-weighted fair value, indicating potential undervaluation supported by strong profitability and efficiency scores. Monte Carlo analysis shows high volatility and a wide value range, with significant downside risk (51.4%) despite substantial upside scenarios. Valuation methods display confidence but reveal mixed signals across growth and liquidity metrics, highlighting investment risk tied to growth uncertainty.